Durvalumab — Dosing in CKD & Dialysis

Durvalumab (Immunotherapy): renal dosing adjustments, dialyzability (Not studied in the label (no statement on removal by dialysis); human IgG1 kappa monoclonal antibody (Imfinzi label 11). Level estimated from molecule size or protein binding; not measured.), and renal-relevant safety risk for CKD

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.